跳到主要內容

很遺憾,我們無法支援你的瀏覽器。如果可以,請升級到新版本,或使用 Mozilla Firefox、Microsoft Edge、Google Chrome 或 Safari 14 或更新版本。如果無法升級,而且需要支援,請將你的回饋寄給我們。

我們衷心感謝你對這個新體驗的回饋。告訴我們你的想法

Elsevier
與我們共同出版

歡迎使用 Elsevier Connect

研究、醫療和技術社群的新聞、資訊和專題。

Students sitting around a table at library

焦點專題

The future we build could depend on research we don’t read

Policy is meant to be shaped by evidence. But what happens when the most relevant research never reaches decision-makers?

New research supported by Elsevier datasets suggests that roughly two-thirds of highly policy-relevant science may go uncited — not because it lacks quality, but because it remains invisible. As AI becomes part of how evidence is found and synthesized, trusted sources, transparency and broader visibility are becoming essential to better decisions.

What if the next life-saving drug is buried in a patent diagram?

In drug discovery, the evidence researchers need often already exists — scattered across journals, patents, figures and chemical diagrams that conventional search may miss.

AI-supported workflows grounded in trusted scientific knowledge are helping researchers connect chemistry, bioactivity and patent evidence faster, with insights traceable back to their sources. From surfacing hidden chemistry in images to exploring millions of drug–disease connections at scale, better access to quality information can help teams move from search to decision with greater confidence.